REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
The review of safety of monoclonal anti-ige-antibodies (xolair) — a new medication for the treatment of severe allergic bronchial asthma is presented. Local and system adverse events, originating after injection of medicament in clinical studies and following administration in patients are discussed...
Saved in:
| Main Author: | A.V. Emel'yanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2008-10-01
|
| Series: | Вопросы современной педиатрии |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/1462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
OMALIZUMAB IN TREATMENT FOR ALLERGIES
by: T.V. Kulichenko
Published: (2007-08-01) -
VII All-Russia Scientific and Practical Congress Healthcare priority national project, problems facing pediatric endocrinology in connectionwith its implementation, 1-2 June 2009, Sankt-Peterburg
by: Andrey Olegovich Emel'yanov
Published: (2009-09-01) -
OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION
by: T.V. Kulichenko
Published: (2007-12-01) -
Prospective study of efficacy and safety of insulin pump therapy in children and adolescents
by: Andrey Olegovich Emel'yanov, et al.
Published: (2010-09-01) -
Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
by: Divya R, et al.
Published: (2020-01-01)